Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients

European Journal of Endocrinology

Volumn 158, Issue 5, 2008, Pages 771-772

  Dora, José Miguel ^a   Leie, Murilo Anderson ^a   Netto, Bruno ^a   Fogliatto, Laura Maria ^b   Silla, Lucia ^b   Torres, Felipe ^b   Maia, Ana Luiza ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; LIOTHYRONINE; RADIOACTIVE IODINE; THYROTROPIN; THYROXINE;

ADULT; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ERROR; PRIORITY JOURNAL; RADIOIODINATION; THYROID DISEASE; THYROID FUNCTION; THYROID WEIGHT; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; THYROID DISEASES; THYROIDECTOMY;

EID: 43149125384     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0006     Document Type: Letter

References (9)

1. Krause DS & Van Etten RA. Tyrosine kinases as targets for cancer therapy. New England Journal of Medicine 2005 353 172-187.
2. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB & Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine 2006 12 908-916.
3. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G & Sauter NP. Altered bone and mineral metabolism in patients receiving imatinib mesylate. New England Journal of Medicine 2006 354 2006-2013.
4. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD & Alexander EK. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Annals of Internal Medicine 2006 145 660-664.
5. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R & Bukowski RM. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute 2007 99 81-83.
6. De Groot JW, Zonnenberg BA, Plukker JT, Van Der Graaf WT & Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clinical Pharmacology and Therapeutics 2005 78 433-438.
7. Faris JE, Moore AF & Daniels GH. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 2007 17 1147-1149.
8. Sichieri R, Baima J, Marante T, De Vasconcellos MT, Moura AS & Vaisman M. Low prevalence of hypothyroidism among black and Mulatto people in a population-based study of Brazilian women. Clinical Endocrinology 2007 66 803-807.
9. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P & Fugazzola L. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. Journal of Clinical Endocrinology and Metabolism 2007 92 3531-3534.